# Versus Systems Inc.: financial statements, quarterly

VS · Nasdaq · CIK 1701963 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vs.md) · [Financials](/companies/vs/financials.md) · [Filings](/companies/vs/filings.md) · [Insiders](/companies/vs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vs/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [23.0](/filings/0001213900-24-098269.md) | [34.2 d](/filings/0001213900-25-026006.md) | [26.5](/filings/0001213900-25-044132.md) | [26.9](/filings/0001213900-25-076539.md) | [3.8](/filings/0001213900-25-110337.md) | [0.0 d](/filings/0001213900-26-044110.md) | [199](/filings/0001213900-26-057987.md) | [(176) d](/filings/0001213900-26-089786.md) | [0.0 d](/filings/0001213900-25-110337.md) | [2,160 d](/filings/0001213900-26-044110.md) | [17.3](/filings/0001213900-26-057987.md) | [6.8](/filings/0001213900-26-089786.md) |
| Cost of revenue | $k | [23.6](/filings/0001213900-24-098269.md) | [23.6 d](/filings/0001213900-25-026006.md) | [24.0](/filings/0001213900-25-044132.md) | [16.2](/filings/0001213900-25-076539.md) | [0.0 d](/filings/0001213900-25-110337.md) | [0.0 d](/filings/0001213900-26-044110.md) | [8.2](/filings/0001213900-26-057987.md) | [8.2](/filings/0001213900-26-089786.md) | [0.0 d](/filings/0001213900-25-110337.md) | [0.0 d](/filings/0001213900-26-044110.md) | not reported | not reported |
| Gross profit | $k | [(0.6)](/filings/0001213900-24-098269.md) | [10.6 d](/filings/0001213900-25-026006.md) | [2.5](/filings/0001213900-25-044132.md) | [10.7](/filings/0001213900-25-076539.md) | [3.8](/filings/0001213900-25-110337.md) | [0.0 d](/filings/0001213900-26-044110.md) | [191](/filings/0001213900-26-057987.md) | [1,972](/filings/0001213900-26-089786.md) | [0.0 d](/filings/0001213900-25-110337.md) | [4.1 d](/filings/0001213900-26-044110.md) | [17.3](/filings/0001213900-26-057987.md) | [1,492](/filings/0001213900-26-089786.md) |
| Research and development | $k | [272](/filings/0001213900-24-098269.md) | [50.3 d](/filings/0001213900-25-026006.md) | [39.4](/filings/0001213900-25-044132.md) | [67.2](/filings/0001213900-25-076539.md) | [11.5](/filings/0001213900-25-110337.md) | [128 d](/filings/0001213900-26-044110.md) | [6.1](/filings/0001213900-26-057987.md) | [6.2](/filings/0001213900-26-089786.md) | [14.5](/filings/0001213900-25-110337.md) | [21.2 d](/filings/0001213900-26-044110.md) | not reported | not reported |
| Selling, general and administrative | $k | [1,617](/filings/0001213900-24-098269.md) | [1,471 d](/filings/0001213900-25-026006.md) | [1,464](/filings/0001213900-25-044132.md) | [1,443](/filings/0001213900-25-076539.md) | [521](/filings/0001213900-25-110337.md) | [881 d](/filings/0001213900-26-044110.md) | [1,358](/filings/0001213900-26-057987.md) | [1,027](/filings/0001213900-26-089786.md) | [742](/filings/0001213900-25-110337.md) | [1,154 d](/filings/0001213900-26-044110.md) | [836](/filings/0001213900-26-057987.md) | [898](/filings/0001213900-26-089786.md) |
| Operating income | $k | [(1,890)](/filings/0001213900-24-098269.md) | [(5,479) d](/filings/0001213900-25-026006.md) | [(1,501)](/filings/0001213900-25-044132.md) | [(1,500)](/filings/0001213900-25-076539.md) | [(529)](/filings/0001213900-25-110337.md) | [(1,009) d](/filings/0001213900-26-044110.md) | [(1,173)](/filings/0001213900-26-057987.md) | [939](/filings/0001213900-26-089786.md) | [(756)](/filings/0001213900-25-110337.md) | [(1,171) d](/filings/0001213900-26-044110.md) | [(819)](/filings/0001213900-26-057987.md) | [594](/filings/0001213900-26-089786.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [1.6](/filings/0001213900-25-110337.md) | [0.0 d](/filings/0001213900-26-044110.md) | not reported | not reported |
| Net income | $k | [(1,382)](/filings/0001213900-24-098269.md) | [(4,508) d](/filings/0001213900-25-026006.md) | [(1,328)](/filings/0001213900-25-044132.md) | [(1,344)](/filings/0001213900-25-076539.md) | [(561)](/filings/0001213900-25-110337.md) | [(810) d](/filings/0001213900-26-044110.md) | [(962)](/filings/0001213900-26-057987.md) | [672](/filings/0001213900-26-089786.md) | [(538)](/filings/0001213900-25-110337.md) | [(965) d](/filings/0001213900-26-044110.md) | [(683)](/filings/0001213900-26-057987.md) | [473](/filings/0001213900-26-089786.md) |
| Diluted EPS | $ per share | [(1.99)](/filings/0001213900-24-098269.md) | not reported | [(0.51)](/filings/0001213900-25-044132.md) | [(0.54)](/filings/0001213900-25-076539.md) | [(0.22)](/filings/0001213900-24-098269.md) | not reported | [(0.20)](/filings/0001213900-26-057987.md) | [0.14](/filings/0001213900-26-089786.md) | not reported | not reported | [(0.14)](/filings/0001213900-26-057987.md) | [0.10](/filings/0001213900-26-089786.md) |
| Basic EPS | $ per share | [(1.99)](/filings/0001213900-24-098269.md) | not reported | [(0.51)](/filings/0001213900-25-044132.md) | [(0.54)](/filings/0001213900-25-076539.md) | [(0.22)](/filings/0001213900-25-110337.md) | not reported | [(0.20)](/filings/0001213900-26-057987.md) | [0.14](/filings/0001213900-26-089786.md) | [(0.11)](/filings/0001213900-25-110337.md) | not reported | [(0.14)](/filings/0001213900-26-057987.md) | [0.10](/filings/0001213900-26-089786.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | period not labelled (2024-08-22) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.7](/filings/0001213900-25-026006.md) | [2.9](/filings/0001213900-24-043555.md) | not reported | not reported | not reported | [3.1](/filings/0001213900-26-044110.md) | [2.4](/filings/0001213900-25-044132.md) | not reported | not reported | [0.5](/filings/0001213900-26-089786.md) | [0.4](/filings/0001213900-26-057987.md) | [1.4](/filings/0001213900-26-089786.md) |
| Current assets | $m | [4.9](/filings/0001213900-25-026006.md) | [3.3](/filings/0001213900-24-043555.md) | [1.8](/filings/0001213900-24-068862.md) | not reported | [1.2](/filings/0001213900-24-098269.md) | [3.5](/filings/0001213900-26-044110.md) | [2.7](/filings/0001213900-25-044132.md) | [3.8](/filings/0001213900-25-076539.md) | [2.8](/filings/0001213900-25-110337.md) | [1.5](/filings/0001213900-26-089786.md) | [0.7](/filings/0001213900-26-057987.md) | [3.0](/filings/0001213900-26-089786.md) |
| Total assets | $m | [4.9](/filings/0001213900-25-026006.md) | [3.4](/filings/0001213900-24-043555.md) | [1.8](/filings/0001213900-24-068862.md) | not reported | [1.2](/filings/0001213900-24-098269.md) | [3.5](/filings/0001213900-26-044110.md) | [2.7](/filings/0001213900-25-044132.md) | [3.8](/filings/0001213900-25-076539.md) | [3.1](/filings/0001213900-25-110337.md) | [2.1](/filings/0001213900-26-089786.md) | [1.7](/filings/0001213900-26-057987.md) | [4.3](/filings/0001213900-26-089786.md) |
| Current liabilities | $m | [0.3](/filings/0001213900-25-026006.md) | [0.2](/filings/0001213900-24-043555.md) | [0.0](/filings/0001213900-24-068862.md) | not reported | [0.0](/filings/0001213900-24-098269.md) | [0.0](/filings/0001213900-26-044110.md) | [0.0](/filings/0001213900-25-044132.md) | [0.0](/filings/0001213900-25-076539.md) | [0.0](/filings/0001213900-25-110337.md) | [0.1](/filings/0001213900-26-089786.md) | [0.5](/filings/0001213900-26-057987.md) | [0.8](/filings/0001213900-26-089786.md) |
| Total liabilities | $m | [0.3](/filings/0001213900-25-026006.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-26-044110.md) | [0.0](/filings/0001213900-25-044132.md) | [0.0](/filings/0001213900-25-076539.md) | [0.0](/filings/0001213900-25-110337.md) | [0.1](/filings/0001213900-26-089786.md) | [0.5](/filings/0001213900-26-057987.md) | [0.8](/filings/0001213900-26-089786.md) |
| Shareholders' equity | $m | [11.9](/filings/0001213900-25-026006.md) | [10.7](/filings/0001213900-24-043555.md) | [9.5](/filings/0001213900-24-068862.md) | [2.5](/filings/0001213900-24-098269.md) | [8.9](/filings/0001213900-24-098269.md) | [11.4](/filings/0001213900-26-044110.md) | [10.8](/filings/0001213900-25-044132.md) | [11.7](/filings/0001213900-25-076539.md) | [11.1](/filings/0001213900-25-110337.md) | [10.2](/filings/0001213900-26-089786.md) | [9.6](/filings/0001213900-26-057987.md) | [11.8](/filings/0001213900-26-089786.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(842) d](/filings/0001213900-24-098269.md) | [(1,226) d](/filings/0001213900-25-026006.md) | [(1,758)](/filings/0001213900-25-044132.md) | [(2,116) d](/filings/0001213900-25-076539.md) | [(381) d](/filings/0001213900-25-110337.md) | [(717) d](/filings/0001213900-26-044110.md) | [(641)](/filings/0001213900-26-057987.md) | [(868) d](/filings/0001213900-26-089786.md) | [24.7 d](/filings/0001213900-25-110337.md) | [(569) d](/filings/0001213900-26-044110.md) | [144](/filings/0001213900-26-057987.md) | [(475) d](/filings/0001213900-26-089786.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [670](/filings/0001213900-24-068862.md) | [670](/filings/0001213900-24-098269.md) | [2,506](/filings/0001213900-25-044132.md) | [2,506](/filings/0001213900-25-076539.md) | [2,506](/filings/0001213900-25-110337.md) | [4,902](/filings/0001213900-26-057987.md) | [4,927](/filings/0001213900-26-089786.md) | [4,902](/filings/0001213900-25-110337.md) | [4,902](/filings/0001213900-26-057987.md) | [4,959](/filings/0001213900-26-089786.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,212,646 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-089786.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.